In a randomized, placebo-controlled, phase III clinical trial, adolescents with moderate-to-severe atopic dermatitis (AD) receiving dupilumab showed significant improvements in clinical signs as demonstrated by Investigator’s Global Assessment (IGA) score reflecting clear (0)/almost clear (1) skin at week 16; however, the IGA may not comprehensively capture the impact of AD, including patient-reported symptoms and health-related quality of life.

The majority of adolescents treated with dupilumab showed statistically significant and clinically meaningful improvements in AD signs, symptoms (including pruritus, sleep loss), and quality of life compared with placebo-treated patients, even among those not achieving IGA 0/1.

The IGA response should be interpreted within the context of additional outcome measures that more comprehensively characterize changes with treatment in AD signs, symptoms, and quality of life in adolescents with moderate-to-severe disease.